Vancomycin - Intermediate/Resistant Staphylococcus Aureus VISA VRSA

VISA and VRSA are staphylococcal bacteria that are less susceptible (VISA) or are fully resistant (VRSA) to the antibiotic agent vancomycin, typically used to treat infections caused by other resistant staphylococcal bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). VISA and VRSA are usually susceptible to other antibiotics, and infections caused by these organisms are treatable.

People who are on prolonged treatment with vancomycin are at highest risk of acquiring VISA or VRSA infections, which are usually acquired in health care settings. Transmission in the community is rare, and healthy individuals are at low risk of acquiring VISA or VRSA infections.

No known cases of VRSA infections have been reported in Wisconsin, and fewer than 20 cases of VISA infections have been reported since they become reportable diseases in 2007.

 

Additional Info Group

Last Revised: January 30, 2015